MA46459A - Méthode de traitement de lésions rénales aiguës - Google Patents

Méthode de traitement de lésions rénales aiguës

Info

Publication number
MA46459A
MA46459A MA046459A MA46459A MA46459A MA 46459 A MA46459 A MA 46459A MA 046459 A MA046459 A MA 046459A MA 46459 A MA46459 A MA 46459A MA 46459 A MA46459 A MA 46459A
Authority
MA
Morocco
Prior art keywords
treatment
acute kidney
kidney damage
acute
damage
Prior art date
Application number
MA046459A
Other languages
English (en)
Other versions
MA46459B1 (fr
Inventor
Bharat Lagu
Michael Patane
Effie Tozzo
Scott Trzaska
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of MA46459A publication Critical patent/MA46459A/fr
Publication of MA46459B1 publication Critical patent/MA46459B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des procédés de traitement d'un patient humain souffrant d'une lésion rénale aiguë.
MA46459A 2016-10-05 2017-10-05 Méthode de traitement de lésions rénales aiguës MA46459B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05
PCT/US2017/055400 WO2018067857A1 (fr) 2016-10-05 2017-10-05 Méthode de traitement de lésions rénales aiguës

Publications (2)

Publication Number Publication Date
MA46459A true MA46459A (fr) 2019-08-14
MA46459B1 MA46459B1 (fr) 2021-03-31

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46459A MA46459B1 (fr) 2016-10-05 2017-10-05 Méthode de traitement de lésions rénales aiguës

Country Status (32)

Country Link
US (1) US20210283116A1 (fr)
EP (1) EP3522880B1 (fr)
JP (1) JP7065839B2 (fr)
KR (1) KR20190062502A (fr)
CN (1) CN109789117B (fr)
AU (1) AU2017340760B2 (fr)
BR (1) BR112019005539A2 (fr)
CA (1) CA3036723A1 (fr)
CO (1) CO2019004561A2 (fr)
CY (1) CY1124759T1 (fr)
DK (1) DK3522880T3 (fr)
ES (1) ES2859487T3 (fr)
HR (1) HRP20210294T1 (fr)
HU (1) HUE053557T2 (fr)
IL (1) IL265749A (fr)
JO (1) JOP20190056B1 (fr)
LT (1) LT3522880T (fr)
MA (1) MA46459B1 (fr)
MD (1) MD3522880T2 (fr)
MX (1) MX2019003949A (fr)
MY (1) MY192385A (fr)
PH (1) PH12019500725A1 (fr)
PL (1) PL3522880T3 (fr)
PT (1) PT3522880T (fr)
RS (1) RS61573B1 (fr)
RU (1) RU2753607C2 (fr)
SG (1) SG11201901925RA (fr)
SI (1) SI3522880T1 (fr)
TW (1) TWI778982B (fr)
UA (1) UA124019C2 (fr)
WO (1) WO2018067857A1 (fr)
ZA (1) ZA201901743B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058154T2 (hu) 2015-10-07 2022-07-28 Mitobridge Inc PPAR agonisták, vegyületek, gyógyászati készítmények és módszerek alkalmazásukra
RU2746602C2 (ru) * 2016-04-13 2021-04-16 Митобридж, Инк. Агонисты ppar, соединения, фармацевтические композиции и способы их применения
CN109843857B (zh) 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
KR20220042150A (ko) * 2019-07-19 2022-04-04 비포르 (인터내셔날) 아게 신장 손상의 예방 및 치료에의 용도를 위한 페로포틴 억제제
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (fr) 2021-03-08 2022-09-15 Abionyx Pharma Sa Composés utiles pour le traitement des maladies du foie

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882524B (zh) 2003-09-19 2011-06-08 詹森药业有限公司 4-((苯氧基烷基)硫基)-苯氧基乙酸及类似物
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
EP2346498B1 (fr) 2008-10-17 2018-12-26 Cymabay Therapeutics, Inc. Procédés de réduction de petites particules denses de ldl
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
US20160015701A1 (en) * 2013-03-08 2016-01-21 Abbive Inc. Methods of Treating Acute Kidney Injury
WO2014165827A1 (fr) * 2013-04-05 2014-10-09 Salk Institute For Biological Studies Antagonistes de ppar
EP2862574A1 (fr) 2013-10-15 2015-04-22 Sanofi Acide {4-[5-(3-chloro-phénoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-diméthyl-phénoxy}-acétique pour son utilisation dans la prévention ou le traitement de l'insuffisance rénale aiguë
US10300108B2 (en) * 2013-12-03 2019-05-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016057658A1 (fr) * 2014-10-08 2016-04-14 Mitobridge, Inc. Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
WO2016057656A1 (fr) * 2014-10-08 2016-04-14 Mitobridge, Inc. Agonistes ppar-delta destinés à être utilisés pour le traitement d'affections mitochondriales, vasculaires, musculaires et démyélynisantes
HUE058154T2 (hu) * 2015-10-07 2022-07-28 Mitobridge Inc PPAR agonisták, vegyületek, gyógyászati készítmények és módszerek alkalmazásukra

Also Published As

Publication number Publication date
HRP20210294T1 (hr) 2021-04-16
CA3036723A1 (fr) 2018-04-12
MD3522880T2 (ro) 2021-03-31
PT3522880T (pt) 2021-02-22
CY1124759T1 (el) 2022-07-22
IL265749A (en) 2019-06-30
AU2017340760A1 (en) 2019-03-21
MX2019003949A (es) 2019-06-10
MY192385A (en) 2022-08-18
EP3522880A1 (fr) 2019-08-14
ZA201901743B (en) 2022-04-28
RU2019111421A3 (fr) 2021-02-05
KR20190062502A (ko) 2019-06-05
JOP20190056B1 (ar) 2022-03-14
DK3522880T3 (en) 2021-01-18
TW201815391A (zh) 2018-05-01
WO2018067857A1 (fr) 2018-04-12
EP3522880B1 (fr) 2020-12-02
RU2019111421A (ru) 2020-11-06
TWI778982B (zh) 2022-10-01
AU2017340760B2 (en) 2023-07-27
PL3522880T3 (pl) 2021-08-23
SI3522880T1 (sl) 2021-07-30
CO2019004561A2 (es) 2019-07-31
US20210283116A1 (en) 2021-09-16
SG11201901925RA (en) 2019-04-29
ES2859487T3 (es) 2021-10-04
PH12019500725A1 (en) 2019-08-05
RU2753607C2 (ru) 2021-08-18
CN109789117B (zh) 2022-08-23
LT3522880T (lt) 2021-03-25
HUE053557T2 (hu) 2021-07-28
JOP20190056A1 (ar) 2019-03-24
RS61573B1 (sr) 2021-04-29
BR112019005539A2 (pt) 2019-06-18
UA124019C2 (uk) 2021-07-07
MA46459B1 (fr) 2021-03-31
JP2019533660A (ja) 2019-11-21
JP7065839B2 (ja) 2022-05-12
CN109789117A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
MA46459A (fr) Méthode de traitement de lésions rénales aiguës
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201790413A1 (ru) Антитела против tigit
ZA201804513B (en) Method of treating c3 glomerulopathy
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
EA201692472A1 (ru) Соединения для лечения рака мозга
MA47408B1 (fr) Traitement du cancer
TR201905233T4 (tr) Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201791101A1 (ru) Способы лечения рассеянного склероза
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
EA201890878A1 (ru) Способ лечения медуллобластомы с помощью ингибитора ezh2
MA52024A (fr) Système de traitement de l'eau
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
SG11201900973PA (en) Transparent skin sample
MA52738A (fr) Méthodes de traitement de l'arthrite psoriasique